Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 11/20 | 0.74 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.72 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.72 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.72 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.69 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | CHUK | O15111 | 2/20 | 0.66 |
| ▸ | DKK1 | O94907 | 1/20 | 0.65 |
| ▸ | GSK3B | P49841 | 1/20 | 0.65 |
| ▸ | PLK1 | P53350 | 1/20 | 0.64 |
| ▸ | JAK2 | O60674 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3519764 | 0.85 | IKBKB (0.97) | IKBKBMAPK8MAPK10CHUKDKK1 | |
| SCHEMBL3519410 | 0.84 | IKBKB (0.79) | IKBKBMAPK8MAPK10MEN1KMT2A | |
| SCHEMBL3518049 | 0.84 | IKBKB (0.79) | IKBKBMAPK8MAPK10CHUKDKK1 | |
| SCHEMBL3520622 | 0.84 | IKBKB (0.79) | IKBKBPIK3CAPIK3CBPIK3CGMAPK8 | |
| SCHEMBL3516622 | 0.84 | IKBKB (1.00) | IKBKBPIK3CAPIK3CBPIK3CGMAPK8 | |
| SCHEMBL3519939 | 0.84 | IKBKB (1.00) | IKBKBMAPK8MAPK10CHUKDKK1 | |
| SCHEMBL3520859 | 0.82 | IKBKB (0.76) | IKBKBPIK3CAPIK3CBPIK3CGMAPK8 | |
| SCHEMBL8313286 | 0.82 | PIK3CG (0.71) | IKBKBPIK3CAPIK3CBPIK3CGMAPK8 | |
| SCHEMBL3520678 | 0.81 | IKBKB (1.00) | IKBKBPIK3CAPIK3CBPIK3CGMAPK8 | |
| SCHEMBL3518043 | 0.81 | IKBKB (0.74) | IKBKBMAPK8MAPK10CHUKDKK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399440-B1 | 5-(2-AMINOPYRIMIDIN-4-YL)BENZISOXAZOLES AS PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20050228005-A1 | Protein kinase inhibitors and uses thereof | MOON YOUNG C | 2005-10-13 | — | — | US | disclosed |
| US-6825190-B2 | 4-(1,2- OR 2,1-BENZOXAZOL-5-YL)-2-AMINOPYRIMIDINES | VERTEX PHARMACEUTICALS INCORPORATED | 2004-11-30 | — | — | US | disclosed |
| WO-2002102800-A9 | 5-(2-AMINOPYRIMIDIN-4-YL) BENZISOXAZOLES AS PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2004-05-06 | — | — | WO | disclosed |
| EP-1399440-A1 | 5-(2-AMINOPYRIMIDIN-4-YL)BENZISOXAZOLES AS PROTEIN KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2004-03-24 | — | — | EP | disclosed |
| US-20040009996-A1 | Protein kinase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2004-01-15 | — | — | US | disclosed |
| WO-2002102800-A1 | 5-(2-AMINOPYRIMIDIN-4-YL) BENZISOXAZOLES AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009996-A1 | Protein kinase inhibitors and uses thereof | GSK3A, GSK3B, JAK3 | IKBKB 488/4885PIK3CA 312/4885PIK3CB 332/4885 |
| US-20050228005-A1 | Protein kinase inhibitors and uses thereof | GSK3A, JAK3, GSK3B | IKBKB 428/4885PIK3CA 310/4885PIK3CB 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.